WO1994017040A1 - Diarylalkyl piperidines useful as multi-drug resistant tumor agents - Google Patents

Diarylalkyl piperidines useful as multi-drug resistant tumor agents Download PDF

Info

Publication number
WO1994017040A1
WO1994017040A1 PCT/US1993/012300 US9312300W WO9417040A1 WO 1994017040 A1 WO1994017040 A1 WO 1994017040A1 US 9312300 W US9312300 W US 9312300W WO 9417040 A1 WO9417040 A1 WO 9417040A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
tumors
compound according
group
formula
Prior art date
Application number
PCT/US1993/012300
Other languages
English (en)
French (fr)
Inventor
Sai P. Sunkara
Jules Freedman
Original Assignee
Merrell Dow Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc. filed Critical Merrell Dow Pharmaceuticals Inc.
Priority to AT94906446T priority Critical patent/ATE150748T1/de
Priority to JP51701194A priority patent/JP3398748B2/ja
Priority to EP94906446A priority patent/EP0680470B1/en
Priority to AU60148/94A priority patent/AU679723B2/en
Priority to CA002152794A priority patent/CA2152794C/en
Priority to DE69309310T priority patent/DE69309310T2/de
Priority to US08/481,538 priority patent/US5648365A/en
Publication of WO1994017040A1 publication Critical patent/WO1994017040A1/en
Priority to NO952885A priority patent/NO305166B1/no
Priority to FI953506A priority patent/FI112474B/fi
Priority to GR970400848T priority patent/GR3023188T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom

Definitions

  • the pump consists of the P-glycoprotein found as a constituent of cell membrane, and it has been suggested that the normal function of the P-glycoprotein is
  • P-glycoprotein is found as a cell membrane constituent in cells of liver, kidney, colon, and jejunum tissues. It has been suggested that P- glycoprotein in the cell membrane of such normal tissues
  • 35 tissue types could explain, at least in part, resistance of various tumors to therapy with standard chemotherapeutic agents.
  • the use of agents which inactivate the P- glycoprotein pump could be therapeutic and valuable in the treatment of multi-drug resistant tumors.
  • n is an integer selected from the group consisting of 0, 1
  • Ri and R 2 are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy, and Ar is phenyl, optionally substituted with from 1 to 3 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, halogen, OCH 2 O,
  • This invention concerns the use of the compounds of Formula 1 as agents effective in reversing drug resistance in multi-drug resistant tumors.
  • the compounds of Formula 1 can be administered together with standard chemotherapeutic agents, can be used in the treatment of tumors which are intrinsically or extrinsically multi-drug resistant, and can be used to reverse resistance in experimental multi- drug resistant tumor cell lines.
  • Multi-drug resistance is defined to be that condition of a tumor cell in which the cell is resistant to a wide variety of unrelated anticancer drugs such as vinca alkaloids, epipodophyllotoxins, dac- tinomycin, and anthracycline classes as well as colchicine. (Goodman and Gilman, 7th Ed., p.
  • This broad based, cross resistance can develop after administration of a single agent of either the vinca alkaloid, epipodophyllo ⁇ toxins, dactinomycin, and anthracycline classes as well as colchicine and is characterized by resistance to the other members of these drug classes.
  • antitumor drugs of the vinca alkaloid class include the naturally occurring vincristine and vinblastine as well as the synthetic derivative vindesine.
  • antitumor drugs of the epipodophyllotoxins class include etoposide and teniposide.
  • An example of an antitumor drug of the anthracycline class is daunorubicin.
  • antitumor drugs of the dactinomycin class include actinomycin A and actinomycin D.
  • (C ⁇ -C 4 )alkoxy means a straight or branched chain alkoxy group having from one to four carbon atoms such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, and the like.
  • the compounds of Formula 1 contain one or more asym ⁇ metric centers and will therefore exist as enantiomers and diastereomers.
  • the carbon atom of the piperidine ring to which the diphenylalkyl group is attached is an asymmetric center.
  • the carbon atom to which these phenyl groups are attached is an asymmetric center.
  • Any reference to the compounds of Formula 1, or any intermediate thereof, should be construed as covering a specific optical isomer, a racemic mixture or a diastereo- metric mixture.
  • the specific optical isomers can be synthesized or can be separated and recovered by techniques known in the art such as chromatography on chiral stationary phases, resolution via chiral salt formation and subsequent separation by selective crystallization, as is known in the art. Alternatively, a chirally pure starting material may be utilized.
  • the appropriately substituted 2- (diphenyl)alkylpiperidine described by structure (1) can be prepared following generally the procedures disclosed in U.S. Patent No. 3,252,983, May 24, 1966 and Sury, E. et al., Helv. Chim. Acta., 1954, 2133.
  • the 2-(diphenyl)alkyl- piperidine can undergo an acylation by treatment with an appropriately substituted acid chloride described by structure (2) to provide the amide described by Formula 1.
  • a suitable organic solvent such as methylene chloride
  • a suitable trialkylamine such as triethylamine
  • the solution is then cooled to approxi- mately 0-5°C.
  • the reaction is allowed to warm to room temperature and stir for approxi ⁇ mately 12 to 24 hours.
  • a suitable organic solvent such as ethyl acetate
  • g refers to grams
  • mg refers to milligrams
  • mmol refers to millimoles
  • ml refers to milliliters
  • °C refers to degrees Celsius
  • the title compound is prepared as a viscous oil from excess triethylamine, 2- (2,2-diphenyl)ethylpiperidine (1.0 eq) and 2-methoxyphenyl- acetyl chloride (1.1 eq) .
  • Example 2 In an analogous manner to Example 1, the title com ⁇ pound, mp 113-114°C, is prepared from excess triethylamine, 2-(2,2-diphenyl)ethylpiperidine (1.0 eq) and 3,4- dimethoxyphenylacetyl chloride (1.1 eq) .
  • Example 2 In an analogous manner to Example 1, the title compound, mp 98-100°C, is prepared from excess triethylamine, 2-(2,2-(4,4'-ditoluoyl)ethylpiperidine (1.0 eq) and 3,4,5-trimethoxyphenylacetyl chloride (1.1 eq) .
  • Example 2 In an analogous manner to Example 1, the title com ⁇ pound, mp 180-181°C, is prepared from excess triethylamine, 2-(2,2-diphenyl)ethylpiperidine (1.0 eq) and indole-3- acetyl chloride (1.1 eq) .
  • a colorimetric assay is employed to determine the sy ⁇ nergy between test compounds of the invention and vinblas- tine or adriamycin against the growth of MDR tumor cells.
  • the assay is based on the ability of live tumor cells to reduce a tetrazoline compound, MTT (3-(4,5-dimethyl)imazol- 2-yl)-2,5-diphenyl tetrazolium bromide, to a blue formazan product.
  • test compound Both the test compound and cytotoxic drug (vinblastine or adriamycin) were added to the cells growing in wells of a 96-well plate at different combinations of concentration. The cells were allowed to grow for 72 hr and, at the end of incubation, stained with MTT for 3 hr. The blue formazan product which developed, was dissolved with DMSO and the color intensity was recorded in a spec- trophotometer. Based on the data, an isobologram analysis was performed. MDR activity (ED 5 o: ⁇ M) represents the concentration of the compound required to lower the IC 50 value of vinblastine by 50% when both the compounds were added to the medium together. Cellular toxicity (ICso: ⁇ M) represents concentration of the compound that inhibit cell growth by 50%. Activity index is the ratio of toxicity and MDR activity.
  • patient used herein is taken to mean mammals such as primates, including humans, and animals such as sheep, horses, cattle, pigs, dogs, cats, rats and mice.
  • the amount of the diarylalkyl piperidine derivative of Formula 1 to be administered can vary widely according to the particular dosage unit employed, the period of treatment, the age and sex of the patient treated, the nature and extent of the multi-drug resistance in the tumor to be treated, and the particular diarylalkyl piperidine derivative selected.
  • the diarylalkyl piperidine derivative is used in conjunction with other chemotherapeutic agents known to be useful in the treatment of tumors.
  • the amount of a diarylalkyl piperidine derivative of Formula 1 effective to reverse multi-drug resistance will generally range from about 15 mg/kg to 500 mg/kg.
  • a unit dosage may contain from 25 to 500 mg of the diarylalkyl piperidine derivative, and can be taken one or more times per day.
  • the diarylalkyl piperidine derivative can be administered with a pharmaceutical carrier using conventional dosage unit forms either orally or parenterally.
  • Tumors which can be treated by the method of this invention include both benign and malignant tumors or neoplasms, and include melanomas, lymphomas, leukemias, and sarcomas.
  • tumors are cutaneous tumors, such as malignant melanomas and mycosis fungoids; hematologic tumors such as leukemias, for example, acute lymphoblastic, acute myelocytic or chronic myelocytic leukemia; lymphomas, such as Hodgkin's disease or malignant lymphoma; gynecologic tumors, such as ovarian and uterine tumors; urologic tumors, such as those of the prostate, bladder or testis; soft tissue sarcomas, osseous or non- osseous sarcomas, breast tumors; tumors of the pituitary, thyroid and adrenal cortex; gastrointestinal tumors, such as those of the esophagus, stomach, intestine and colon; pancreatic and hepatic tumors; laryngeal papillomestasas and lung tumors.
  • those tumors which typically are or become multi-drug resistant are most beneficially treated with the compounds and methods of this
  • chemotherapeutic agents used together with the diarylalkyl piperidines of Formula 1 are those cytotoxic agents commonly used in the treatment of tumors.
  • Illustra ⁇ tive examples of chemotherapeutic agents are: cyclophospha- mide, methotrexate, prednisone, 6-mercaptopurine, procarba- zine, daunorubicin, vincristine, vinblastine, chlorambucil, cytosine arabinoside, 6-thioguanine, thio TEPA, 5-fluo- rouracil, 5-fluoro-2deoxyudirinde, 5-azacytidine, nitrogen mustard, l,3-bis(2chloroethyl)-l-nitrosourea (BCNU), (l-(2- chloroethyl)-3cyclohexyl-l-nitrosourea) (CCNU), busulfan, adriamycin, bleomycin, vindesine, cycloleucine or
  • chemotherapeutic agent used in the method of this invention varies widely and depends on factors such as the patient, the tumor tissue type and its size, and the particular chemotherapeutic agent selected.
  • the amount is any effective amount and can be readily determined by those skilled in the art. In general, less chemotherapeutic agent will be required when administered with the diarylalkyl piperidines of Formula 1, primarily because the problem of drug resistance need not addressed by the addition of larger quantities of chemotherapeutic agent.
  • mixtures of chemotherapeutic agents may be employed and surgical excision and radiation therapy may be useful adjuvants as in any tumor therapy.
  • the preferred route of administration is oral administration.
  • the derivative can be formulated into solid or liquid preparations such as capsules, pills, tablets, troches, lozenges, melts, powders, solutions, suspensions, or emulsions.
  • the solid unit dosage forms can be a capsule which can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers such as lactose, sucrose, calcium phosphate, and cornstarch.
  • the compounds of this invention can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch, or gelatin, disintegrating agents intended to assist the breakup and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and guar gum, lubricants intended to improve the flow of tablet granulations and to prevent the adhesion of tablet material to the surfaces of the tablet dies and punches, for example, talc, stearic acid, or magnesium, calcium, or zinc stearate, dyes, coloring agents, and flavoring agents intended to enhance the esthetic qualities of the tablets and make them more acceptable to the patient.
  • conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch, or gelatin
  • disintegrating agents intended to assist the breakup and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch
  • Suitable excipients for use in oral liquid dosage forms include diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptably surfactant, suspending agent, or emulsifying agent.
  • diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptably surfactant, suspending agent, or emulsifying agent.
  • the diarylalkyl piperidine derivatives of this invention may also be administered parenterally, that is, subcutaneously, intravenously, intramuscularly, or inter- peritoneally, as injectable dosages of the compound in a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid or mixture of liquids such as water, saline, aqueous dextrose and related sugar solutions, an alcohol such as ethanol, isopropanol, or hexadecyl alcohol, glycols such as propylene glycol or polyethylene glycol, glycerol ketals such as 2,2-dimethyl- l,3-dioxolane-4-methanol, ethers such as polyethyleneglycol 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant such as a soap or a detergent,
  • Suitable fatty acids include oleic acid, stearic acid, and isostearic acid.
  • Suitable fatty acid esters are, for example, ethyl oleate and isopropyl myristate.
  • Suitable soaps include fatty alkali metal, ammonium, and triethanolamine salts and suitable detergents include cationic detergents, for example, dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamines acetates; anionic detergents, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates; nonionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers; and amphoteric detergents, for example, alkyl- ⁇ -aminopropionates, and 2- alkylimidazoline quaternary ammonium salts, as well as mixtures.
  • the parenteral compositions of this invention will typically contain from about 0.5 to about 25% by weight of the ox
  • the compounds of this invention can also be administered topically. This can be accomplished by simply preparing a solution of the compound to be administered, preferably using a solvent known to promote transdermal absorption such as ethanol or dimethyl sulfoxide (DMSO) with or without other excipients.
  • a solvent known to promote transdermal absorption such as ethanol or dimethyl sulfoxide (DMSO) with or without other excipients.
  • Topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety.
  • trans- dermal devices are described in U.S. Pat. Nos. 3,742,951, 3,797,494, 3,996,934, and 4,031,894. These devices generally contain a backing member which defines one of its face ' surfaces, an active agent permeable adhesive layer defining the other face surface and at least one reservoir containing the active agent interposed between the face surfaces.
  • the active agent may be contained in a plurality of microcapsules distributed throughout the permeable adhesive layer.
  • the active agent is delivered continuously from the reservoir or microcap- sules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient.
  • the encapsulating agent may also function as the membrane.
  • the pharmaceutically active compound is contained in a matrix from which it is delivered in the desired gradual, constant and controlled rate.
  • the matrix is permeable to the release of the compound through diffusion or microporous flow.
  • the release is rate controlling.
  • Such a system, which requires no membrane is described in U.S. Pat. No. 3,921,636. At least two types of release are possible in these systems. Release by diffusion occurs when the matrix is nonporous.
  • the pharmaceutically effective compound dissolves in and diffuses through the matrix itself. Release by microporous flow occurs when the pharmaceuti ⁇ cally effective compound is transported through a liquid phase in the pores of the matrix.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/US1993/012300 1993-01-21 1993-12-17 Diarylalkyl piperidines useful as multi-drug resistant tumor agents WO1994017040A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AT94906446T ATE150748T1 (de) 1993-01-21 1993-12-17 Als mittel gegen mehrfach resistente tumorenverwendbare diarylalkylpiperidine
JP51701194A JP3398748B2 (ja) 1993-01-21 1993-12-17 多剤耐性腫瘍剤として有用なジアリールアルキルピペリジン類
EP94906446A EP0680470B1 (en) 1993-01-21 1993-12-17 Diarylalkyl piperidines useful as multi-drug resistant tumor agents
AU60148/94A AU679723B2 (en) 1993-01-21 1993-12-17 Diarylalkyl piperidines useful as multi-drug resistant tumoragents
CA002152794A CA2152794C (en) 1993-01-21 1993-12-17 Diarylalkyl piperidines useful as multi-drug resistant tumor agents
DE69309310T DE69309310T2 (de) 1993-01-21 1993-12-17 Als mittel gegen mehrfach resistente tumorenverwendbare diarylalkylpiperidine
US08/481,538 US5648365A (en) 1993-01-21 1993-12-17 Diarylalkyl piperidines useful as multi-drug resistant tumor agents
NO952885A NO305166B1 (no) 1993-01-21 1995-07-20 Diarylalkylpiperidiner og farmas°ytisk preparat inneholdende disse
FI953506A FI112474B (fi) 1993-01-21 1995-07-20 Menetelmä kasvainlääkkeinä käyttökelpoisten diaryylialkyylipiperidiiniyhdisteiden valmistamiseksi
GR970400848T GR3023188T3 (en) 1993-01-21 1997-04-21 Diarylalkyl piperidines useful as multi-drug resistant tumor agents.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US656993A 1993-01-21 1993-01-21
US006,569 1993-01-21

Publications (1)

Publication Number Publication Date
WO1994017040A1 true WO1994017040A1 (en) 1994-08-04

Family

ID=21721516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/012300 WO1994017040A1 (en) 1993-01-21 1993-12-17 Diarylalkyl piperidines useful as multi-drug resistant tumor agents

Country Status (20)

Country Link
US (1) US5648365A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0680470B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3398748B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100377280B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE150748T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU679723B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2152794C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69309310T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0680470T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2102830T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI112474B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3023188T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT72078A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL108369A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9400563A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO305166B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ261414A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW243445B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994017040A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA94317B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US7476680B2 (en) 2000-10-17 2009-01-13 H. Lee Moffitt Cancer Center & Research Institute, Inc. Substituted heterocyclic compounds for treating multidrug resistance
CN110372571A (zh) * 2018-04-12 2019-10-25 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503957A (ja) * 1992-02-06 1995-04-27 メレルダウファーマスーティカルズ　インコーポレイテッド トリフェニルアザシクロアルカン誘導体類による多剤耐性の逆転
AU6366000A (en) * 1999-07-23 2001-02-13 Colorado State University Research Foundation Multidrug resistance pump inhibitors and uses thereof
US20030109448A1 (en) * 2001-11-07 2003-06-12 Crowley Kathleen S. Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US8153184B2 (en) * 2001-11-26 2012-04-10 Samsung Mobile Display Co., Ltd. Organic EL display device and method of manufacturing the same
KR100656490B1 (ko) 2001-11-26 2006-12-12 삼성에스디아이 주식회사 풀칼라 유기전계 발광표시소자 및 그의 제조방법
EP2984073B1 (en) 2013-02-08 2018-10-24 General Mills, Inc. Reduced sodium food product

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016044A1 (en) * 1992-02-06 1993-08-19 Merrell Dow Pharmaceuticals Inc. Reversal of multi-drug resistance by triphenyl-azacycloalkane derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1049377B (de) * 1952-04-03 1959-01-29 Abbott Laboratories, North Chicago, 111. (V. St. A.) Verfahren zur Herstellung von substituierten Vinylpiperidinen
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US3956296A (en) * 1974-12-11 1976-05-11 A. H. Robins Company, Incorporated 1-Substituted-4-benzylpiperidines
US4035372A (en) * 1976-08-13 1977-07-12 G. D. Searle & Co. 4-{[4-(Diphenylmethyl)-1-piperidinyl]methyl}benzenamines
EP0228893A3 (en) * 1985-12-20 1990-01-03 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US4990511A (en) * 1988-08-03 1991-02-05 Takeda Chemical Industries, Ltd. Amide compounds, their production and use
DK0409406T3 (da) * 1989-06-19 1994-02-07 Wellcome Found Arylsubstituerede aminderivater, der er anvendelige ved cancerterapi
GB9000305D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Anticholinergic agents
EP0467435A3 (en) * 1990-07-19 1992-04-01 Akzo N.V. Benzhydryl derivatives having calmodulin inhibitor properties
DK0471612T3 (da) * 1990-08-14 1999-02-22 Hoechst Marion Roussel Inc Nye 19-nor steroider med carbonkæde omfattende en amidgruppe i 11-beta-stillingen, fremgangsmåde til deres fremstilling, de

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016044A1 (en) * 1992-02-06 1993-08-19 Merrell Dow Pharmaceuticals Inc. Reversal of multi-drug resistance by triphenyl-azacycloalkane derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Columbus, Ohio, US; *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US7304053B2 (en) 2000-10-17 2007-12-04 H. Lee Moffitt Cancer Center & Research Institute, Inc. Substituted heterocyclic compounds for treating multidrug resistance
US7476680B2 (en) 2000-10-17 2009-01-13 H. Lee Moffitt Cancer Center & Research Institute, Inc. Substituted heterocyclic compounds for treating multidrug resistance
CN110372571A (zh) * 2018-04-12 2019-10-25 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物
CN110372571B (zh) * 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物

Also Published As

Publication number Publication date
TW243445B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-03-21
HU9502195D0 (en) 1995-09-28
GR3023188T3 (en) 1997-07-30
EP0680470A1 (en) 1995-11-08
NZ261414A (en) 1997-06-24
CA2152794A1 (en) 1994-08-04
NO952885L (no) 1995-09-20
US5648365A (en) 1997-07-15
CA2152794C (en) 1999-04-06
JP3398748B2 (ja) 2003-04-21
FI953506A0 (fi) 1995-07-20
NO305166B1 (no) 1999-04-12
MX9400563A (es) 1994-07-29
EP0680470B1 (en) 1997-03-26
KR960700230A (ko) 1996-01-19
ES2102830T3 (es) 1997-08-01
FI953506L (fi) 1995-07-20
KR100377280B1 (ko) 2003-07-18
DE69309310D1 (de) 1997-04-30
DK0680470T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-04-28
ZA94317B (en) 1994-08-18
AU679723B2 (en) 1997-07-10
IL108369A (en) 1999-08-17
IL108369A0 (en) 1994-04-12
HUT72078A (en) 1996-03-28
FI112474B (fi) 2003-12-15
AU6014894A (en) 1994-08-15
DE69309310T2 (de) 1997-11-06
JPH08505870A (ja) 1996-06-25
ATE150748T1 (de) 1997-04-15
NO952885D0 (no) 1995-07-20

Similar Documents

Publication Publication Date Title
KR0165131B1 (ko) 1,4-벤조티아제핀 유도체
EP0680470B1 (en) Diarylalkyl piperidines useful as multi-drug resistant tumor agents
US5364843A (en) Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
US5665780A (en) Reversal of multi-drug resistance by tetraarylethylenes
US4061746A (en) Lactamimide inhibitors of gastrointestinal hypersecretion
EP0643693B1 (en) Reversal of multi-drug resistance by triphenyl-piperidine derivatives
US4616017A (en) Aminohydroxypropoxy substituted aryl compounds
US5182293A (en) Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones
CA2176016A1 (en) Antiarrhythmic benzodiazepines
US5190957A (en) Treatment of multi-drug resistant tumors with quinolyl-and isoquinolyloxazole-2-ones
US5670521A (en) Reversal of multi-drug resistance by triphenyl-azacycloalkane derivatives
EP0428107B1 (en) Use of quinolyl-and isoquinolyloxanole-2-ones for the production of a medicament for the treatment of multi-drug resistant tumors
JP2835730B2 (ja) １，４−ジ置換ピペジニル化合物類
KR100618006B1 (ko) 나프티리딘 유도체
JP2002138089A (ja) ナフチリジン誘導体
HU203474B (en) Process for producing pharmaceutical compositions for treating ulcus ventriculi
MXPA00009358A (en) Barbituric acid derivative and preventive and therapeutic agent for bone and cartilage containing the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2152794

Country of ref document: CA

AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 261414

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1994906446

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019950702950

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 953506

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1994906446

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 08481538

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 1994906446

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 953506

Country of ref document: FI